![image(1)](https://static.packgene.com/wp-content/uploads/2024/03/image1.jpg)
NXL-004 is an innovative treatment approach developed based on Professor Chen Gong’s pioneering in situ differentiation technology platform. It is notably the first AAV gene therapy product for malignant glioblastoma to receive FDA orphan drug designation. The therapy targets glioblastoma cells by overexpressing the neurogenic transcription factor NeuroD1, inhibiting tumor cell proliferation while promoting their differentiation into neurons. This mechanism offers potential advantages over conventional treatments such as radiotherapy and chemotherapy, with minimal side effects on surrounding tissues.
The initial patient, suffering from recurrent glioblastoma, underwent surgery and dosing without complications. Postoperative observations revealed a stable condition with no significant adverse reactions, culminating in a smooth recovery and discharge within a week. This successful administration of AAV-NeuroD1 gene therapy represents a groundbreaking leap from preclinical research to clinical application, offering hope for improved treatment outcomes in glioblastoma patients.
Professor Huang Yulun expressed optimism regarding the therapy’s safety and efficacy, citing promising preclinical data and the favorable safety profile observed in the first clinical trial subject. Likewise, Professor Chen Gong, the founder of NeuExcell Therapeutics, commended Professor Huang Yulun’s team for their collaboration and surgical expertise, underscoring the significance of this milestone in advancing neurological disease treatments.
The successful dosing of NXL-004 at Suzhou Dushu Lake Hospital underscores the potential of gene therapy in revolutionizing the management of malignant glioblastoma, addressing the urgent need for more effective treatment options in neuro-oncology. This achievement serves as a testament to the collaborative efforts of researchers and medical professionals in pushing the boundaries of medical science for the benefit of patients worldwide.
https://mp.weixin.qq.com/s/sOHG3tioxVxfwTRKWBSejQ
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)